LAS VEGAS, June 20, 2018 /PRNewswire/ -- Digipath, Inc. (OTCQB: DIGP), a service-oriented independent testing laboratory and media firm focused on the developing cannabis market, is pleased to announce that it was awarded Emerald Badges for its performance in the Spring 2018 Emerald Test for proficiency in a variety of cannabis tests, including potency in oil, heavy metals, terpenes, microbial 1 (quantitative), microbial 2 (qualitative salmonella), shiga-toxin expressing E. coli (STEC), aspergillus mold, and mycotoxins.
The Emerald Test™ is an Inter-Laboratory Comparison and Proficiency Test (ILC/PT) program for cannabis testing labs. It brings to the cannabis industry a well-established standard for testing in the environmental, food, pharmaceutical, water, and petrochemical testing industries.
Emerald Badges are awarded to the top performing labs in each proficiency test category, with criteria established by the ISO-accredited PT manufacturer. Labs that receive a Badge are not only recognized for their capabilities in comparison to their peers within a given series, but also for their commitment to good science in the cannabis industry.
Todd Denkin, President and COO of Digipath Labs, commented, "Participating in blinded, third party facilitated proficiency testing at least twice every year demonstrates Digipath Labs' commitment to continuous improvement and to being the best cannabis testing laboratory in Nevada and wherever else we may open."
About Digipath, Inc.
Digipath, Inc. supports the cannabis industry's best practices for reliable testing, cannabis education and training, and brings unbiased cannabis news coverage to the cannabis industry. Digipath Labs provides pharmaceutical-grade analysis and testing to the cannabis industry to ensure producers, consumers, and patients know exactly what is in the cannabis they make and to help maximize the quality of its client's products through analysis, research, development, and standardization.
Investor Relations Contact
Viridian Capital Advisors, LLC
Information about Forward-Looking Statements
This press release contains "forward-looking statements" that include information relating to future events. Forward-looking statements should not be read as a guarantee of future performance or results and will not necessarily be accurate indications of the times at, or by, which that performance or those results will be achieved. Forward-looking statements are based on information available at the time they are made and/or management's good faith belief as of that time with respect to future events and are subject to risks and uncertainties that could cause actual performance or results to differ materially from those expressed in, or suggested by, the forward-looking statements. Important factors that could cause these differences include, but are not limited to: the Company's need for additional funding, the demand for the Company's products, governmental regulation of the cannabis industry, the Company's ability to maintain customer and strategic business relationships, the impact of competitive products and pricing, growth in targeted markets, the adequacy of the Company's liquidity and financial strength to support its growth, and other risks that may be detailed from time-to-time in the Company's filings with the United States Securities and Exchange Commission. For a more detailed description of the risk factors and uncertainties affecting Digipath, please refer to the Company's recent Securities and Exchange Commission filings, which are available at www.sec.gov. The Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise.
SOURCE Digipath, Inc.